Haematology
Explore our latest news, features and educational resources in this specialist area.
Fostamatinib not recommended for refractory chronic immune thrombocytopenia
The cost-effectiveness estimates for fostamatinib compared with rituximab are higher than what NICE normally considers cost effective.
NICE recommends first treatment for rare blood disorder
Midostaurin is reocmmended as a treatment for advanced systemic mastocytosis in adults. It the first targeted therapy for this condition to be available on the NHS.
SMC accepts treatment for primary chronic immune thrombocytopenia
Avatrombopag is accepted for restricted use within NHS Scotland.
NICE publishes new rapid guideline to diagnose and treat rare blood clotting condition associated with COVID-19 vaccination
NICE has today published a new rapid COVID-19 guideline to help healthcare staff identify and treat patients who develop the rare syndrome vaccine-induced immune thrombocytopenia and thrombosis (VITT) after receiving COVID-19 vaccinations.
